{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-001074","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.110393+00:00","generated_at":"2026-06-07T03:53:58.923224+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Cocrystal reports favorable preliminary safety for CDI-988 (Phase 1) and CC-42344 (Phase 2a) antivirals","bullets":["CDI-988 (pan-norovirus/coronavirus 3CL protease inhibitor) Phase 1 in Australia shows favorable safety in single-ascending dose cohorts.","CC-42344 (influenza A PB2 inhibitor) Phase 2a in UK shows favorable tolerability in first cohort of challenge study.","Cocrystal expects to report topline results for both Phase 1 and Phase 2a studies in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-001074","json":"https://secwatch.observer/filing/0001493152-24-001074.json","markdown":"https://secwatch.observer/filing/0001493152-24-001074.md","text":"https://secwatch.observer/filing/0001493152-24-001074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224001074/0001493152-24-001074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224001074/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:53:58.923224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}